BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Genetown

  Affinivax Closes $120 Million Financing Round to Support Vaccine Development Program

  Cambridge, Mass.-based Affinivax completed a $120 million Series B financing round that will be used to advance its vaccine and immunotherapy candidates.

  April 23, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Beach

  Research Roundup: New Protein Linked to Alzheimer’s Identified and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  April 23, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  AGT CEO Jeff Galvin on the Future of the Gene and Cell Therapy Industry

  Jeff Galvin, CEO of American Gene Technologies (AGT), had 30 years of business and entrepreneurial experience in Silicon Valley during the formative years of the personal computing and internet era.

  April 23, 2020

   · 

  4 min read

   · 

  Gina Hagler
• 

  Business

  BioSpace Movers & Shakers, April 24

  Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.

  April 23, 2020

   · 

  8 min read

   · 

  Alex Keown
• 

  Business

  Vaccine Expert Claims He Was Ousted for Opposing White House’s Promotion of Unproven COVID-19 Drugs

  In a statement to the New York Times, Bright said he has pushed for science, not politics, as the key to battling the pandemic.

  April 23, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  GlobalData Report: Top 20 Pharma Companies Lost $2.6 Trillion Market Cap in Q1

  The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.

  April 23, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Pluristem Advances Placental Cells to Modulate COVID-19 Cytokine Storm

  Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.

  April 23, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Biotech Bay

  Leaked Study Data Suggests Gilead’s Remdesivir Did Not Benefit COVID-19 Patients

  Shares of Gilead Sciences fell after reports suggest remdesivir failed to distinguish itself as a treatment for COVID-19 in a clinical study conducted in China. But, there are some questions about the veracity of the study.

  April 23, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Moderna’s COVID-19 Vaccine Clinical Trial Moves into 2nd Round of Dosing

  On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.

  April 23, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: April 23

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.

  April 23, 2020

   · 

  5 min read

   · 

  BioSpace Editorial Staff